You are here » Home » Companies » Company Overview » Anuh Pharma Ltd

Anuh Pharma Ltd.

BSE: 506260 Sector: Health care
NSE: N.A. ISIN Code: INE489G01022
BSE 00:00 | 28 Jan 127.60 1.20
(0.95%)
OPEN

125.25

HIGH

129.00

LOW

124.30

NSE 05:30 | 01 Jan Anuh Pharma Ltd
OPEN 125.25
PREVIOUS CLOSE 126.40
VOLUME 34943
52-Week high 218.70
52-Week low 48.70
P/E 22.23
Mkt Cap.(Rs cr) 640
Buy Price 128.00
Buy Qty 100.00
Sell Price 128.90
Sell Qty 25.00
OPEN 125.25
CLOSE 126.40
VOLUME 34943
52-Week high 218.70
52-Week low 48.70
P/E 22.23
Mkt Cap.(Rs cr) 640
Buy Price 128.00
Buy Qty 100.00
Sell Price 128.90
Sell Qty 25.00

Anuh Pharma Ltd. (ANUHPHARMA) - Chairman Speech

Company chairman speech

Dear Shareholders

One of the great privileges of working in Pharmaceutical industry is the opportunity todirectly contribute towards the advancement quality of life. This has always been ourgreatest source of purpose in propelling Anuh Pharma forward. Today as the world faces anunprecedented pandemic we continue playing our part in serving humanity.

It gives me great pleasure to present to you our Company's 60th Annualreport in a nutshell.

Our Operational Revenue for the Financial year 2019-20 amounted to Rs 30695 Lakhs asagainst Rs 32066 Lakhs for the previous year a decrease of 4.27 %.

Our PBT has gone down from Rs 3240 lakhs to Rs 1916 lakhs for this year. The mainreasons for the decrease in revenue & PBT are as follows:

I. Export restrictions imposed by Indian Government on majority of the products forFebruary and March 2020. This step was taken by Government to avoid shortages in India.

II. We had to write off huge depreciation due to commissioning of our expansionproject.

EXPANSION PROJECT:

We are pleased to inform you that our "NEW EXPANSION PROJECT" is fullyoperational and due to this increased capacity we hope to achieve at least 30% additionalrevenue in 20202021.

Moreover we have started validation batches for:

1. Telmisartan

2. Glyclazide 3. Moxifloxacin 4. INH and we propose to start commercial productionduring 2nd half of 2020-2021.

We continue to allocate total resources towards building the API & Bulk DrugSegment. Our state-of-the-art R&D Facility at Navi Mumbai works relentlessly on thedevelopment of newer and better pharmaceutical raw material.

An advance stage works is going on for the following products:

1. Aripiprazole

2. Olanzapine

3. Fexofenadine

4. Sitagliptin

5. Celecoxib

COVID 19 CRISIS :

Even during COVID 19 crisis we were successful in running our plant continuouslybeing an essential drug company.

We are fully complying to requisite safety norms like social distancing sanitisingtemperature monitoring masking etc.

To ensure presence of maximum staff & workers we have provided "pick up &drop facility" and also incentivised the employees.

GLOBAL cGMP COMPLIANCE :

During 2019-2020 we were inspected by USFDA authorities and we are pleased to informthat we have successfully cleared the USFDA inspection without any observations by the USauthorities.

Adherence to the stringent cGMP requirements of global regulators is a non-compromisingobjective for us. Compliance to these standards has become a key determinant of futuresuccess for the API industry. We continue to invest significant time & resources inensuring that we remain committed to 24/7 cGMP compliance. Over the past years our cGMPcapabilities have increased significantly. We recognise this as a pertinent area and aretargeting appropriate technology based solutions to facilitate cGMP compliance with anincreased focus on requisite manpower training.

TRANSFORMATION:

In order to generate long term sustainable value for Shareholders businesses need tocontinuously involve & transform themselves to build a strong foundation for futuregrowth. At Anuh Pharma we have decided on a transformational journey to make Anuh Pharma aCompany that is in tune with the times.

With Warm Regards

Mr. Bipin N. Shah

Manging Director

Anuh Pharma Ltd.

.